Narrow search
Showing 1 - 10 of 35,859
Cover Image
Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis: Focus on Critically Ill Patients
Reboli, Annette C.; Rotstein, Coleman; Kett, Daniel H.; … - In: PharmacoEconomics 29 (2011) 8, pp. 705-717
Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized … patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C … intravenously daily) versus those of fluconazole (800 mg intravenously on day 1, then 400 mg intravenously daily) as first …
Persistent link: https://www.econbiz.de/10010614308
Cover Image
The Clinical and Economic Potential of Cyclosporin Drug Interactions
Martin, Jill E.; Daoud, A. Jamal; Schroeder, Timothy J.; … - In: PharmacoEconomics 15 (1999) 4, pp. 317-337
recognised. Included in this list are the azole antifungal drugs, ketoconazole, fluconazole and itraconazole; the calcium channel …
Persistent link: https://www.econbiz.de/10005449102
Cover Image
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS: An Overview and Methodological Discussion
Freedberg, Kenneth A.; Paltiel, A. David - In: PharmacoEconomics 14 (1998) 2, pp. 165-174
Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...
Persistent link: https://www.econbiz.de/10005449227
Cover Image
Cost Effectiveness of Oral Terbinafine (Lamisil(R)) Compared with Oral Fluconazole (Diflucan(R)) in the Treatment of Patients with Toenail Onychomycosis
Salo, Heini; Pekurinen, Markku - In: PharmacoEconomics 20 (2002) 5, pp. 319-324
Objective: To determine the cost effectiveness of terbinafine (Lamisil(R)) tablets compared with fluconazole (Diflucan … fluconazole 150mg once weekly for 12 weeks (n = 45) or 24 weeks (n = 44) in patients with culture-confirmed toenail onychomycosis … fluconazole groups. We subsequently used these data to calculate the cost effectiveness of the three treatment regimens, defining …
Persistent link: https://www.econbiz.de/10005449011
Cover Image
Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails: A US Analysis
Gupta, Aditya K. - In: PharmacoEconomics 13 (1998) 2, pp. 243-256
and fluconazole, the armamentarium of drugs available to treat onychomycosis has expanded. The objective of this study was … and pulse), terbinafine and fluconazole. The mycological cure rates [mean +- standard error (SE)] from the meta … +- 7% and fluconazole 59%. The cost per mycological cure was griseofulvin $US8089, itraconazole (continuous) $US1877 …
Persistent link: https://www.econbiz.de/10005405008
Cover Image
Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis
Joish, Vijay N.; Armstrong, Edward P. - In: PharmacoEconomics 19 (2001) 10, pp. 983-1002
The incidence of fungal nail infections is increasing and this is possibly because of several factors: better methods of detection, a growing population of immunocompromised patients who have a greater susceptibility to such infections, the increased use of immunosuppressive drugs, the...
Persistent link: https://www.econbiz.de/10005590302
Cover Image
Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B Monotherapy: Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients in the UK
Flynn, Terry N.; Kelsey, Stephen M.; Hazel, Dena L.; … - In: PharmacoEconomics 16 (1999) 5, pp. 543-550
Objective: To assess the economic impact of adding granulocyte colony-stimulating factor (G-CSF) to amphotericin B to treat a presumed deep-seated fungal infection in neutropenic patients. This study was conducted from the perspective of the National Health Service (NHS) hospital sector. Design:...
Persistent link: https://www.econbiz.de/10005404823
Cover Image
Economic Evaluations of Treatments for Systemic Fungal Infections: A Systematic Review of the Literature
Dixon, Simon; McKeen, Emma; Tabberer, Margaret; … - In: PharmacoEconomics 22 (2004) 7, pp. 421-433
We systematically reviewed published economic evaluations of systemic antifungal therapies and assessed their strengths and weaknesses. The study identified all economic evaluations published before May 2002 and critically appraised their methods using a published checklist. Over 1000 papers on...
Persistent link: https://www.econbiz.de/10005243130
Cover Image
Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
de Vries, Robin; Daenen, Simon; Tolley, Keith; … - In: PharmacoEconomics 26 (2008) 1, pp. 75-90
difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used. Objective: To … assess the cost effectiveness of itraconazole compared with both fluconazole and no prophylaxis for the prevention of … fluconazole and itraconazole and no prophylaxis. The perspective of the analysis was that of the healthcare sector; only medical …
Persistent link: https://www.econbiz.de/10005590491
Cover Image
Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS
Kempen, John H.; Frick, Kevin D.; Jabs, Douglas A. - In: PharmacoEconomics 19 (2001) 12, pp. 1199-1208
Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior...
Persistent link: https://www.econbiz.de/10005404898